<!DOCTYPE html><html lang="en-us" >


<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  
  
  
    <meta name="generator" content="Wowchemy 5.6.0 for Hugo" />
  

  
  












  
  










  







  
  

  
  
  

  
  
  
  
  
  

  

  
  
  
    
  
  <meta name="description" content="A highly-customizable Hugo documentation theme powered by Wowchemy website builder." />

  
  <link rel="alternate" hreflang="en-us" href="https://example.com/tag/immunotherapy/" />

  
  
  
    <meta name="theme-color" content="#1565c0" />
  

  
  
    
    <script src="/js/mathjax-config.js"></script>
  

  

  <link rel="stylesheet" href="/css/vendor-bundle.min.c7b8d9abd591ba2253ea42747e3ac3f5.css" media="print" onload="this.media='all'">

  
  
  
    
    

    
    
    
    
      
      
    
    
    

    
    
    

    

    
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
    
      
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      
      

      
      

      
    
      
      

      
      

      
    
  

  
  
  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.7579f2ea081d74b9cb40a7d984071feb.css" />

  
  
  
  
  
  
  
    
    
    <link rel="stylesheet" href="/css/libs/chroma/github-light.min.css" title="hl-light" media="print" onload="this.media='all'" >
    <link rel="stylesheet" href="/css/libs/chroma/dracula.min.css" title="hl-dark" media="print" onload="this.media='all'" disabled>
  

  
  



  


  


  




  
  
  

  
  
    <link rel="alternate" href="/tag/immunotherapy/index.xml" type="application/rss+xml" title="BM Sci-Tech Memento" />
  

  
  
    <link rel="manifest" href="/manifest.webmanifest" />
  

  
  <link rel="icon" type="image/png" href="/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_32x32_fill_lanczos_center_3.png" />
  <link rel="apple-touch-icon" type="image/png" href="/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_180x180_fill_lanczos_center_3.png" />

  <link rel="canonical" href="https://example.com/tag/immunotherapy/" />

  
  
  
  
  
  
  
  
    
    
  
  

  
  
    
    
  
  <meta property="twitter:card" content="summary" />
  
    <meta property="twitter:site" content="@wowchemy" />
    <meta property="twitter:creator" content="@wowchemy" />
  
  <meta property="og:site_name" content="BM Sci-Tech Memento" />
  <meta property="og:url" content="https://example.com/tag/immunotherapy/" />
  <meta property="og:title" content="Immunotherapy | BM Sci-Tech Memento" />
  <meta property="og:description" content="A highly-customizable Hugo documentation theme powered by Wowchemy website builder." /><meta property="og:image" content="https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png" />
    <meta property="twitter:image" content="https://example.com/media/icon_hu1efa9af2edf414d45fb59503b457ea16_13437_512x512_fill_lanczos_center_3.png" /><meta property="og:locale" content="en-us" />
  
    
      <meta property="og:updated_time" content="2022-12-16T00:00:00&#43;00:00" />
    
  

  



  


  <title>Immunotherapy | BM Sci-Tech Memento</title>

  
  
  
  











</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper   "  >

  
  
  
  
  
  
  
  
  
  <script src="/js/wowchemy-init.min.613040fe4f2c0f007b4dcb64404201cb.js"></script>

  


<aside class="search-modal" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#" aria-label="Close"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control"
        aria-label="Search...">
        
      </div>

      
      

      

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>



  <div class="page-header">
    












<header class="header--fixed">
  <nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
    <div class="container-xl">

      
      <div class="d-none d-lg-inline-flex">
        <a class="navbar-brand" href="/">BM Sci-Tech Memento</a>
      </div>
      

      
      <button type="button" class="navbar-toggler" data-toggle="collapse"
              data-target="#navbar-content" aria-controls="navbar-content" aria-expanded="false" aria-label="Toggle navigation">
      <span><i class="fas fa-bars"></i></span>
      </button>
      

      
      <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
        <a class="navbar-brand" href="/">BM Sci-Tech Memento</a>
      </div>
      

      
      
      <div class="navbar-collapse main-menu-item collapse justify-content-end" id="navbar-content">

        
        <ul class="navbar-nav d-md-inline-flex">
          

          

          
          
          

          

          
          
          
          

          
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/"><span>Home</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/tool/"><span>Tools</span></a>
          </li>

          
          

          

          
          
          
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="/docs/"><span>Notes</span></a>
          </li>

          
          

          

          
          
          
            
              
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="https://pubmed.ncbi.nlm.nih.gov/" target="_blank" rel="noopener"><span>PubMed</span></a>
          </li>

          
          

          

          
          
          
            
              
            
          

          

          
          
          
          

          
            
              
              
            
            
          

          <li class="nav-item">
            <a class="nav-link " href="https://licore.netlify.app/" target="_blank" rel="noopener"><span>MII</span></a>
          </li>

          
          

        

          
        </ul>
      </div>

      <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">

        
        

        
        
        <li class="nav-item">
          <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
        </li>
        

        
        
        
        <li class="nav-item dropdown theme-dropdown">
          <a href="#" class="nav-link" data-toggle="dropdown" aria-haspopup="true" aria-label="Display preferences">
            <i class="fas fa-moon" aria-hidden="true"></i>
          </a>
          <div class="dropdown-menu">
            <a href="#" class="dropdown-item js-set-theme-light">
              <span>Light</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-dark">
              <span>Dark</span>
            </a>
            <a href="#" class="dropdown-item js-set-theme-auto">
              <span>Automatic</span>
            </a>
          </div>
        </li>
        

        
        

      </ul>

    </div>
  </nav>
</header>


  </div>

  <div class="page-body">
    
    
    

    












  

  
  
  
    
  
<div class="universal-wrapper pt-3">
  <h1>Immunotherapy</h1>

  

  
</div>



<div class="universal-wrapper">
  

  
  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/35926817/" >PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy</a>
    </div>

    
    <a href="/article/35926817/"  class="summary-link">
      <div class="article-style">
        Highlights
PARPI plus radiation further activated cGAS/STING pathway than single treatment. PARPI plus radiation upregulated the expression of PD-L1. PARPI plus radiation sensitizes small cell lung cancer to anti-PD-1 immunotherapy. Abstract
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Monday, 01 August 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.sciencedirect.com/science/article/abs/pii/S0304383522003366" target="_blank" rel="noopener">
    Cancer Letters</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35926817/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/35926817/" >
      <img src="/article/35926817/featured_hu691566d3736453f8c9871b62a0d0238b_77488_150x0_resize_q75_h2_lanczos.webp" height="61" width="150"
           alt="PARP inhibitor plus radiotherapy reshapes an inflamed tumor microenvironment that sensitizes small cell lung cancer to the anti-PD-1 immunotherapy" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/35617682/" >Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease</a>
    </div>

    
    <a href="/article/35617682/"  class="summary-link">
      <div class="article-style">
        Key Points
For 105 patients enrolled in 5 trials, the overall response rate after 8 or 12 weeks’ LD IL-2 was 48.6% and 53.3% with continued therapy. Skin involvement was the most frequent (84%); the organ-specific response rate was highest in liver (66.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Friday, 29 July 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://ashpublications.org/bloodadvances/article/6/15/4392/485387/Organ-specific-response-after-low-dose-interleukin" target="_blank" rel="noopener">
    Blood Advances</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35617682/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636330/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/35617682/" >
      <img src="/article/35617682/featured_hu0b6ee708167ca72af7d9b319937ed590_68052_150x0_resize_q75_h2_lanczos.webp" height="54" width="150"
           alt="Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/review/35868279/" >Designing antibodies as therapeutics</a>
    </div>

    
    <a href="/review/35868279/"  class="summary-link">
      <div class="article-style">
        Abstract
Antibody therapeutics are a large and rapidly expanding drug class providing major health benefits. We provide a snapshot of current antibody therapeutics including their formats, common targets, therapeutic areas, and routes of administration.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Thursday, 21 July 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.cell.com/cell/fulltext/S0092-8674%2822%2900699-7" target="_blank" rel="noopener">
    Cell</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35868279/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/review/35868279/" >
      <img src="/review/35868279/featured_hu7dbef217355916940ef076e95b54ef44_104993_150x0_resize_q75_h2_lanczos.webp" height="117" width="150"
           alt="Designing antibodies as therapeutics" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/35868534/" >Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway</a>
    </div>

    
    <a href="/article/35868534/"  class="summary-link">
      <div class="article-style">
        Highlights
LINC01085 is deleted in hormone-independent prostate cancer (HIPC) which can predict better outcomes of HIPC patients. LINC01085 acts as a tumor suppressor in the tumourigenicity and metastasis of HIPC. LINC01085 exerts its functions by both interacting with TBK1 and GSK3β, accelerated TBK1 phosphorylation at the Ser-172 site, in HIPC.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Tuesday, 19 July 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.sciencedirect.com/science/article/abs/pii/S0304383522003135" target="_blank" rel="noopener">
    Cancer Letters</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35868534/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/35868534/" >
      <img src="/article/35868534/featured_hu5427bdc779234ba976b3141f429d2f5e_80319_150x0_resize_q75_h2_lanczos.webp" height="126" width="150"
           alt="Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/review/35817212/" >HuR as a molecular target for cancer therapeutics and immune-related disorders</a>
    </div>

    
    <a href="/review/35817212/"  class="summary-link">
      <div class="article-style">
        Abstract
The control of eukaryotic gene expression occurs at multiple levels, from transcription to messenger RNA processing, transport, localization, turnover, and translation. RNA-binding proteins control gene expression and are involved in different stages of mRNA processing, including splicing, maturation, turnover, and translation.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Friday, 08 July 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.sciencedirect.com/science/article/abs/pii/S0169409X22003325" target="_blank" rel="noopener">
    Advanced Drug Delivery Reviews</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35817212/" target="_blank" rel="noopener">
    PubMed</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/review/35817212/" >
      <img src="/review/35817212/featured_hu743cd2306d3735bfc2c3da8d0c486304_173787_150x0_resize_q75_h2_lanczos.webp" height="162" width="150"
           alt="HuR as a molecular target for cancer therapeutics and immune-related disorders" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/35775486/" >Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models</a>
    </div>

    
    <a href="/article/35775486/"  class="summary-link">
      <div class="article-style">
        Abstract
Immunosuppressive cells accumulating in the tumor microenvironment constitute a formidable barrier that interferes with current immunotherapeutic approaches. A unifying feature of these tumor-associated immune and vascular endothelial cells appears to be the elevated expression of ectonucleotidase CD39, which in tandem with ecto-5&rsquo;-nucleotidase CD73, catalyzes the conversion of extracellular ATP into adenosine.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Friday, 01 July 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.jci.org/articles/view/157431" target="_blank" rel="noopener">
    Journal of Clinical Investigation</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35775486/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246388/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/35775486/" >
      <img src="/article/35775486/featured_hu3f691aa45a9803d5f5c014c7f4704128_110842_150x0_resize_q75_h2_lanczos.webp" height="108" width="150"
           alt="Glycoengineered anti-CD39 promotes anticancer responses by depleting suppressive cells and inhibiting angiogenesis in tumor models" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/35768164/" >NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome</a>
    </div>

    
    <a href="/article/35768164/"  class="summary-link">
      <div class="article-style">
        Abstract
Background: Because of the shortage of ideal cell surface antigens, the development of T-cell receptor (TCR)-engineered T cells (TCR-T) that target intracellular antigens such as NY-ESO-1 is a promising approach for treating patients with solid tumors.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Wednesday, 29 June 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://jitc.bmj.com/content/10/6/e003811.long" target="_blank" rel="noopener">
    The Journal for ImmunoTherapy of Cancer</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35768164/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244667/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/35768164/" >
      <img src="/article/35768164/featured_hu5b2e718d4d8c383af3cd1065872b24b2_115615_150x0_resize_q75_h2_lanczos.webp" height="103" width="150"
           alt="NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/35728871/" >Hypoxia-inducible lentiviral gene expression in engineered human macrophages</a>
    </div>

    
    <a href="/article/35728871/"  class="summary-link">
      <div class="article-style">
        Abstract
Background: Human immune cells, including monocyte-derived macrophages, can be engineered to deliver proinflammatory cytokines, bispecific antibodies, and chimeric antigen receptors to support immune responses in different disease settings. When gene expression is regulated by constitutively active promoters, lentiviral payload gene expression is unregulated, and can result in potentially toxic quantities of proteins.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Tuesday, 21 June 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://jitc.bmj.com/content/10/6/e003770.long" target="_blank" rel="noopener">
    The Journal for ImmunoTherapy of Cancer</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35728871/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214393/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/review/35681719/" >Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System</a>
    </div>

    
    <a href="/review/35681719/"  class="summary-link">
      <div class="article-style">
        Abstract
Hyperoxia is used in order to counteract hypoxia effects in the TME (tumor microenvironment), which are described to boost the malignant tumor phenotype and poor prognosis. The reduction of tumor hypoxic state through the formation of a non-aberrant vasculature or an increase in the toxicity of the therapeutic agent improves the efficacy of therapies such as chemotherapy.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Tuesday, 31 May 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.mdpi.com/2072-6694/14/11/2740" target="_blank" rel="noopener">
    Cancers</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35681719/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179641/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/review/35681719/" >
      <img src="/review/35681719/featured_hu1663a2d01a25074aeb416b0766138584_748709_150x0_resize_q75_h2_lanczos.webp" height="85" width="150"
           alt="Implications of Hyperoxia over the Tumor Microenvironment: An Overview Highlighting the Importance of the Immune System" loading="lazy">
    </a>
    
  </div>
</div>

  
    













  


<div class="media stream-item view-compact">
  <div class="media-body">

    <div class="section-subheading article-title mb-0 mt-0">
      <a href="/article/35580929/" >CD4&#43; T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy</a>
    </div>

    
    <a href="/article/35580929/"  class="summary-link">
      <div class="article-style">
        Abstract
Background: Antitumor therapeutic vaccines are generally based on antigenic epitopes presented by major histocompatibility complex (MHC-I) molecules to induce tumor-specific CD8+ T cells. Paradoxically, continuous T cell receptor (TCR) stimulation from tumor-derived CD8+ T-cell epitopes can drive the functional exhaustion of tumor-specific CD8+ T cells.
      </div>
    </a>
    

    <div class="stream-meta article-metadata">

      

      
        


<div class="article-metadata">

  
  

  
  <span class="article-date">
    
    
      
    
    Monday, 16 May 2022 
  </span>
  

  

  

  
  
  
  

  
  

</div>

      
    </div>

    
    <div class="btn-links">
      








  


















  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://jitc.bmj.com/content/10/5/e004022" target="_blank" rel="noopener">
    The Journal for ImmunoTherapy of Cancer</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://pubmed.ncbi.nlm.nih.gov/35580929/" target="_blank" rel="noopener">
    PubMed</a>

  
  
  
    
  
  
  
  
  
    
  
  <a class="btn btn-outline-primary btn-page-header btn-sm" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114852/" target="_blank" rel="noopener">
    PMC</a>


    </div>
    

  </div>
  <div class="ml-3">
    
    
    
    <a href="/article/35580929/" >
      <img src="/article/35580929/featured_hu83294e71479e7cf218e21e9053187d85_138002_150x0_resize_q75_h2_lanczos.webp" height="213" width="150"
           alt="CD4&#43; T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy" loading="lazy">
    </a>
    
  </div>
</div>

  

  
<nav class="mt-1">
  <ul class="pagination justify-content-center">
    
    <li class="page-item"><a class="page-link" href="/tag/immunotherapy/">&laquo;</a></li>
    
    
    <li class="page-item"><a class="page-link" href="/tag/immunotherapy/page/3/">&raquo;</a></li>
    
  </ul>
</nav>


</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">

  












  

  

  

  
  






  
  <p class="powered-by copyright-license-text">
    Copyright © 2023 | Biomedist | All rights reserved.
  </p>
  




  <p class="powered-by">
    
    
    
      
      
      
      
      
      
      Published with <a href="https://wowchemy.com/?utm_campaign=poweredby" target="_blank" rel="noopener">Wowchemy</a> — the free, <a href="https://github.com/wowchemy/wowchemy-hugo-themes" target="_blank" rel="noopener">open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  


<script src="/js/vendor-bundle.min.d26509351aa0ff874abbee824e982e9b.js"></script>




  

  
  

  













  
  <script id="search-hit-fuse-template" type="text/x-template">
    <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
    </div>
  </script>
  
    <script src="https://cdn.jsdelivr.net/gh/krisk/Fuse@v3.2.1/dist/fuse.min.js" integrity="sha512-o38bmzBGX+hD3JHWUFCDA09btWaqrNmoJ3RXLlrysA7PP01Kgs4UlE4MhelE1v5dJR3+cxlR4qQlotsW7jKsnw==" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/gh/julmot/mark.js@8.11.1/dist/jquery.mark.min.js" integrity="sha512-mhbv5DqBMgrWL+32MmsDOt/OAvqr/cHimk6B8y/bx/xS88MVkYGPiVv2ixKVrkywF2qHplNRUvFsAHUdxZ3Krg==" crossorigin="anonymous"></script>
  












  
  
  
  
  
  
  







<script id="page-data" type="application/json">{"use_headroom":true}</script>



  <script src="/js/wowchemy-headroom.c251366b4128fd5e6b046d4c97a62a51.js" type="module"></script>








  
  


<script src="/en/js/wowchemy.min.54dd6e4d8f2e4b1d098381b57f18dd83.js"></script>























</body>
</html>
